Published in Gut on October 01, 1976
Liver biopsy: techniques, clinical applications, and complications. Br Med J (Clin Res Ed) (1984) 1.68
Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening" severe exacerbation of chronic hepatitis B. World J Gastroenterol (2005) 1.02
A clinicopathological study of liver disease in haemophiliacs. J Clin Pathol (1978) 1.02
Effects of prednisolone/azathioprine in chronic hepatitis B viral infection. Gut (1982) 0.90
Immunological changes in liver disease. Proc R Soc Med (1977) 0.89
Assessment of the (14C) aminopyrine breath test in liver disease. Gut (1978) 0.89
Historical treatment of chronic hepatitis B and chronic hepatitis C. Gut (1993) 0.81
Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses. Gut (1991) 0.77
Chronic active hepatitis: a sixteen year survey at a district general hospital. Postgrad Med J (1989) 0.76
Chronic hepatitis in the 1980s. Br Med J (Clin Res Ed) (1985) 0.75
Prognostic determinants in chronic hepatitis B infection-a reevaluation. West J Med (1978) 0.75
Effect of short-term prednisolone therapy in patients with severe chronic type B hepatitis. Korean J Intern Med (1989) 0.75
Dangers of immunosuppressive therapy in hepatitis B virus carriers. CMAJ (1992) 0.75
Specialty conference: Chronic hepatitis B. West J Med (1978) 0.75
The comparison of percentages in matched samples. Biometrika (1950) 8.93
A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med (1967) 7.00
A classification of chronic hepatitis. Lancet (1968) 6.07
Hemagglutination assay for antigen and antibody associated with viral hepatitis. Science (1970) 5.81
Association between polyarteritis and Australia antigen. Lancet (1970) 4.32
Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology (1972) 4.29
Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125 I-antibody. J Immunol (1972) 4.25
Relation of Australia-SH antigen to the willowbrook MS-2 strain. N Engl J Med (1969) 4.13
Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med (1971) 3.23
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet (1971) 2.64
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut (1975) 1.72
Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Engl J Med (1971) 1.60
Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet (1972) 1.59
Distinctions in chronic active hepatitis based on circulating hepatitis-associated antigen. Lancet (1970) 1.46
Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol (1972) 1.40
Chronic hepatitis. Gut (1974) 1.30
Detection of antibody to hepatitis-associated antigen in hemophilia patients and in voluntary blood donors. Vox Sang (1973) 1.29
Serum autoantibodies and immunoglobulins in hepatitis-associated antigen (HAA)-positive and -negative liver disease. Gut (1973) 0.97
Classification and treatment of chronic active liver disease. Gastroenterology (1968) 0.93
Interrelations of hepatitis B antigen and autoantibodies in chronic idiopathic liver disease. Gastroenterology (1972) 0.87
Chronic liver disease and hepatitis-B antigen: a prospective study. Br Med J (1974) 0.86
Hepatitis with Australia antigenemia following renal transplantation. Can Med Assoc J (1973) 0.86
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology (1972) 4.29
Remission of seizures and relapse in patients with epilepsy. Epilepsia (1979) 4.17
An influenza simulation model for immunization studies. Am J Epidemiol (1976) 4.12
Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med (1978) 2.99
Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc (1976) 2.93
Diabetes mellitus: incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945-1970. Diabetes (1976) 2.89
Seizures after head trauma: a population study. Neurology (1980) 2.87
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology (1992) 2.82
Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med (1973) 2.81
Measurement of gastric functions during digestion of ordinary solid meals in man. Gastroenterology (1976) 2.56
Subclinical hepatic encephalopathy impairs daily functioning. Hepatology (1998) 2.23
Patterns of canine gastric electrical activity. Am J Physiol (1969) 2.15
Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. Am J Clin Pathol (1992) 2.12
Effect of preoperative antibiotic regimen on development of infection after intestinal surgery: Prospective, randomized, double-blind study. Ann Surg (1974) 2.03
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03
Screening of subclinical hepatic encephalopathy. J Hepatol (2000) 1.96
The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clin Proc (1977) 1.95
Primary hyperparathyroidism: a prospective clinical study. Am J Med (1971) 1.93
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology (1970) 1.86
Occlusion of the jejunum for intestinal perfusion in man. Mayo Clin Proc (1966) 1.85
Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med (1984) 1.85
A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med (1982) 1.82
Cold pressor test as a predictor of hypertension. Hypertension (1984) 1.77
Health, normality, and the ghost of Gauss. JAMA (1970) 1.75
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Early cirrhosis--or primary cholangitis? Lancet (1997) 1.74
Coronary heart disease in residents of Rochester, Minnesota. II. Mortality, incidence, and survivorship, 1950-1975. Mayo Clin Proc (1981) 1.73
Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.72
Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut (1975) 1.72
Different gastric, pancreatic, and biliary responses to solid-liquid or homogenized meals. Dig Dis Sci (1979) 1.72
Anti-Salmonella agglutinins in chronic active liver disease. Lancet (1971) 1.67
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Rectal cancer following colectomy for polyposis. Arch Surg (1980) 1.63
The risk of epilepsy following febrile convulsions. Neurology (1979) 1.61
Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis (1971) 1.61
Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc (1985) 1.59
Transient cerebral ischemic attacks in a community. Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc (1973) 1.59
Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology (1995) 1.57
Mortality in patients with epilepsy. Epilepsia (1980) 1.56
Hepatitis B vaccination and preterm infants. Pediatr Infect Dis J (1993) 1.55
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat (2003) 1.53
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53
Gastric emptying and secretion of bile acids, cholesterol, and pancreatic enzymes during digestion. Duodenal perfusion studies in healthy subjects. Mayo Clin Proc (1974) 1.53
Follow-up clinical results in patients undergoing percutaneous transluminal coronary angioplasty. Circulation (1985) 1.51
Pancreozymin bioassay in man based on pancreatic enzyme secretion: potency of specific amino acids and other digestive products. J Clin Invest (1970) 1.51
Gastric secretion and emptying after ordinary meals in duodenal ulcer. Gastroenterology (1977) 1.51
The relation of age and sex to distribution of values in healthy adults of serum calcium, inorganic phosphorus, magnesium, alkaline phosphatase, total proteins, albumin, and blood urea. J Lab Clin Med (1969) 1.50
Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant (2001) 1.50
Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol (2000) 1.49
Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation (1981) 1.49
The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol (1986) 1.48
Water and electrolyte transport during maintenance of isotonicity in human jejunum and ileum. J Lab Clin Med (1967) 1.45
Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood (1972) 1.45
Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol (1983) 1.45
Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology (1991) 1.44
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine (1997) 1.44
The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol (2000) 1.44
Electron microscopic studies of viral agents in Crohn's disease. Lancet (1976) 1.43
Lymphocyte cytotoxicity and inhibition studied with autologous liver cells: observations in chronic active liver disease and the primary biliary cirrhosis syndrome. Gastroenterology (1976) 1.43
Cultivation of viral agents from Crohn's disease. A new sensitive system. Lancet (1976) 1.42
Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology. N Engl J Med (1974) 1.42
Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy. Eur J Gastroenterol Hepatol (1997) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol (2000) 1.41
'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol (2001) 1.41
Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol (1972) 1.40
Inheritance of very low serum dopamine-beta-hydroxylase activity. Am J Hum Genet (1975) 1.40
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40
Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acid. Gastroenterology (1970) 1.40
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 1.38
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology (1999) 1.38
A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther (1998) 1.38
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res (1993) 1.37
The placebo effect of transcutaneous electrical stimulation. Pain (1978) 1.37
Hepatitis-associated antigen screening by automated complement fixation: comparison with manual methods. Am J Clin Pathol (1973) 1.37
Jejunal secretion of electrolytes and water in nontropical sprue. J Lab Clin Med (1969) 1.36
Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother (1994) 1.36
Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther (1998) 1.36
Impaired cholecystokinin-pancreozymin secretion, intraluminal dilution, and maldigestion of fat in sprue. Gastroenterology (1972) 1.35
Disturbances in fat digestion induced by acidic jejunal pH due to gastric hypersecretion in man. Gastroenterology (1970) 1.33
Coronary heart disease in residents of Rochester, Minnesota, 1950-1975. I. Background and study design. Mayo Clin Proc (1981) 1.33
Arteriographic patterns early in the onset of the coronary syndromes. Br Heart J (1975) 1.32
Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol (1994) 1.31
Aorta-coronary artery saphenous vein bypass surgery: clinical and angiographic results. Mayo Clin Proc (1975) 1.31
Hepatic failure and the kidney. Gastroenterology (1966) 1.31
Bile acid secretion and biliary bile acid composition altered by cholecystectomy. Am J Dig Dis (1973) 1.30
Sequence analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands. J Clin Microbiol (1994) 1.30
Detection of long-lasting antibody to hepatitis E virus in a US traveller to Pakistan. Lancet (1992) 1.29
An improved diluent for rubella hemagglutination and hemagglutination-inhibition tests. Appl Microbiol (1968) 1.28
Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med (1970) 1.28
Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature (1974) 1.28